Extending the use of biologics to mucous membranes by attachment of a binding domain

[1]  P. Fallon,et al.  The IL-1 cytokine family as custodians of barrier immunity. , 2022, Cytokine.

[2]  R. Ratnapriya,et al.  IL-17 Producing Lymphocytes Cause Dry Eye and Corneal Disease With Aging in RXRα Mutant Mouse , 2022, Frontiers in Medicine.

[3]  Jun Zhu,et al.  Application of Animal Models in Interpreting Dry Eye Disease , 2022, Frontiers in Medicine.

[4]  P. Argüeso.  Human ocular mucins: the endowed guardians of sight. , 2021, Advanced drug delivery reviews.

[5]  Yong Ho Kim,et al.  Experimental Models, Induction Protocols, and Measured Parameters in Dry Eye Disease: Focusing on Practical Implications for Experimental Research , 2021, International Journal of Molecular Sciences.

[6]  S. Ahadian,et al.  Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies. , 2021, International journal of pharmaceutics.

[7]  S. Barabino.  A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic , 2021, Ophthalmology and Therapy.

[8]  Liangmin Yu,et al.  Sustained Release Systems for Delivery of Therapeutic Peptide/Protein. , 2021, Biomacromolecules.

[9]  S. D. De Smedt,et al.  Challenges and strategies for the delivery of biologics to the cornea. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[10]  M. McGeachy,et al.  IL-17 in the Pathogenesis of Disease: Good Intentions Gone Awry. , 2021, Annual review of immunology.

[11]  A. Nokhodchi,et al.  Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus , 2020, Biomedicines.

[12]  V. Perez,et al.  Inflammatory basis for dry eye disease flares. , 2020, Experimental eye research.

[13]  P. Morgan,et al.  The impact of contact lens wear on ocular surface mucins using a novel clinical fluorescence imaging system. , 2020, Contact lens & anterior eye : the journal of the British Contact Lens Association.

[14]  P. Aragona,et al.  Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review , 2020, British Journal of Ophthalmology.

[15]  W. Foulsham,et al.  The role of Th17 immunity in chronic ocular surface disorders. , 2020, The ocular surface.

[16]  R. Dana,et al.  Pigment Epithelium-derived factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease. , 2020, The ocular surface.

[17]  L. Fugger,et al.  Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases , 2020, Cell.

[18]  Hsin-Jung Li,et al.  Development of therapeutic antibodies for the treatment of diseases , 2020, Journal of Biomedical Science.

[19]  N. McNamara,et al.  Use of Collagen Binding Domains to Deliver Molecules to the Cornea. , 2019, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[20]  C. Garlanda,et al.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. , 2019, Immunity.

[21]  W. Foulsham,et al.  The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease. , 2018, The ocular surface.

[22]  Mary Joseph,et al.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches☆ , 2018, Advanced drug delivery reviews.

[23]  S. Feizi,et al.  Therapeutic approaches for corneal neovascularization , 2017, Eye and Vision.

[24]  N. McNamara,et al.  Aire-deficient mice provide a model of corneal and lacrimal gland neuropathy in Sjögren's syndrome , 2017, PloS one.

[25]  R. Dana,et al.  IFN-γ–Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity , 2017, The Journal of Immunology.

[26]  Ying Zheng,et al.  Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics , 2017, Front. Pharmacol..

[27]  D. Schaumberg,et al.  TFOS DEWS II Epidemiology Report. , 2017, The ocular surface.

[28]  J. Wolffsohn,et al.  TFOS DEWS II Diagnostic Methodology report. , 2017, The ocular surface.

[29]  R. Dana,et al.  TFOS DEWS II Management and Therapy Report. , 2017, The ocular surface.

[30]  Stefano Bonini,et al.  TFOS DEWS II pathophysiology report. , 2017, The ocular surface.

[31]  M. Labetoulle,et al.  Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. , 2017, The ocular surface.

[32]  R. Dana,et al.  T Cell–Derived Granulocyte-Macrophage Colony-Stimulating Factor Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+ Myeloid Cell Maturation and Migration , 2017, Investigative ophthalmology & visual science.

[33]  Idan Cohen,et al.  Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations , 2016, International journal of cell biology.

[34]  C. Dong,et al.  Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. , 2016, International immunology.

[35]  B. An,et al.  Collagen interactions: Drug design and delivery. , 2016, Advanced drug delivery reviews.

[36]  Dong Hyun Kim,et al.  Topical TSG-6 Administration Protects the Ocular Surface in Two Mouse Models of Inflammation-Related Dry Eye. , 2015, Investigative ophthalmology & visual science.

[37]  G. Laurie,et al.  Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease. , 2014, Investigative ophthalmology & visual science.

[38]  Richard T. Lee,et al.  Targeted Delivery to Cartilage Is Critical for In Vivo Efficacy of Insulin‐like Growth Factor 1 in a Rat Model of Osteoarthritis , 2014, Arthritis & rheumatology.

[39]  X. Tan,et al.  Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome , 2014, Eye.

[40]  R. Dana,et al.  Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. , 2013, JAMA ophthalmology.

[41]  Hyun Soo Lee,et al.  Chronic Dry Eye Disease is Principally Mediated by Effector Memory Th17 Cells , 2013, Mucosal Immunology.

[42]  Bracken M. King,et al.  Design of a superior cytokine antagonist for topical ophthalmic use , 2013, Proceedings of the National Academy of Sciences.

[43]  R. Dana,et al.  Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. , 2012, American journal of ophthalmology.

[44]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[45]  Ying-Ting Chen,et al.  Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjögren's syndrome , 2012, Laboratory Investigation.

[46]  J. Klarlund,et al.  Brief treatment with heparin-binding EGF-like growth factor, but not with EGF, is sufficient to accelerate epithelial wound healing. , 2011, Biochimica et biophysica acta.

[47]  G. Norman.  Likert scales, levels of measurement and the “laws” of statistics , 2010, Advances in health sciences education : theory and practice.

[48]  De-Quan Li,et al.  IL-17 disrupts corneal barrier following desiccating stress , 2009, Mucosal Immunology.

[49]  T. Nishida,et al.  Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. , 2009, Investigative ophthalmology & visual science.

[50]  R. Dana,et al.  Autoimmunity in Dry Eye Is Due to Resistance of Th17 to Treg Suppression1 , 2009, The Journal of Immunology.

[51]  S. Pflugfelder,et al.  Corneal thickness is reduced in dry eye. , 1999, Cornea.

[52]  D. Wigley,et al.  The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. , 1994, Journal of molecular biology.

[53]  G. Snibson,et al.  Ocular Surface Residence Times of Artificial Tear Solutions , 1992, Cornea.

[54]  P. Binder,et al.  Lectin Binding Patterns of the Human Cornea Comparison of Frozen and Paraffin Sections , 1988, Cornea.

[55]  C. Wright.  Structural comparison of the two distinct sugar binding sites in wheat germ agglutinin isolectin II. , 1984, Journal of molecular biology.

[56]  N. Gokhale,et al.  Inflammation and dry eye disease-where are we? , 2022, International journal of ophthalmology.

[57]  C. Hanna,et al.  Effects of drug vehicles on ocular contact time. , 1975, Archives of ophthalmology.